XORTX Therapeutics (XORTX Therapeutics) Debt-to-Asset : 0.00 (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is XORTX Therapeutics Debt-to-Asset?

XORTX Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.03 Mil. XORTX Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. XORTX Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was $6.64 Mil. XORTX Therapeutics's debt to asset for the quarter that ended in Sep. 2023 was 0.00.

XORTX Therapeutics Debt-to-Asset Historical Data

The historical data trend for XORTX Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Debt-to-Asset Chart

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

0.03

0.05

0.01

XORTX Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	-

Competitive Comparison of XORTX Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, XORTX Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XORTX Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's Debt-to-Asset falls into.

XORTX Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

XORTX Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.066	+	0.011)	/	12.344
	=	0.01

XORTX Therapeutics's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.029	+	0)	/	6.64
	=	0.00

XORTX Therapeutics (NAS:XRTX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

XORTX Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics (XORTX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

ANUA:Germany XRTX:Canada

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.